Market news

Motley Fool Press Release.

IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.

Tipranks Press Release.

Despite a 7% revenue dip from retina headwinds, IRIDEX Corp (IRIX) posts record glaucoma probe volume and reaffirms full-year guidance.

Moby summary of IRIDEX Corporation's Q2 2026 earnings call

Iridex: Q2 Earnings Snapshot

MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026. Second Quarter 2026 Financial Highlights Generated total revenue of $12.6 million, compared to $13.6 million in the prior year periodCyclo G6® product family reven

MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the second quarter 2026 and provide a business update after the close of trading on August 18, 2026. The Company’s management team will host a corresponding conference call beginning a

MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company’s line of EndoProbe® Handpieces. Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Hand